Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada
(TSX:GUD),(NASDAQ:COLL), MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM(TM) (methylphenidate HCI extended-release capsules) in Canada. JORNAY PM(TM) is an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children 6-12 […]